# Kelly Ryerson

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/kelly-ryerson
Canonical HTML page: https://getyourbrief.com/entity/kelly-ryerson

## Recent coverage (4 stories, network-wide)

### 8 Months, Zero Action: EPA's Broken MAHA Promise Invites Legal and Political Fallout
2026-07-12 00:32:37 · Sector: legal · Sentiment: Negative · Impact: 6/10 · Sources: 8

The EPA's failure to deliver a promised MAHA regulatory agenda after eight months exposes the agency to accountability pressures, including potential lawsuits and legislative oversight, while raising questions about good-faith regulatory planning.
Full story: https://getlegalbrief.com/story/epa-maha-agenda-broken-promise-legal-fallout

### EPA's 8-Month MAHA Silence Leaves Chronic Disease Interventions in Limbo
2026-07-12 00:32:29 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 8

The indefinite postponement of a formal MAHA agenda means delayed federal action on pesticides and chemicals linked to America's chronic disease epidemic, frustrating health advocates and potentially costing lives.
Full story: https://gethealthbrief.com/story/epa-maha-health-agenda-chronic-disease-delay

### As Regulations Roll Back, EPA's 8-Month MAHA Gap Underscores Policy Disconnect
2026-07-12 00:32:19 · Sector: climate · Sentiment: Negative · Impact: 6/10 · Sources: 8

The EPA's simultaneous retreat from a promised health agenda and aggressive environmental deregulation highlights a hollowing out of environmental governance, raising concerns about the agency's ability to address the health impacts of climate change.
Full story: https://getclimatebrief.com/story/epa-maha-climate-health-policy-gap

### Pharma and Ag Biotech Face Regulatory Fog as EPA's MAHA Agenda Hits 8-Month Void
2026-07-12 00:32:09 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 8

The lack of a clear MAHA framework from the EPA creates uncertainty for biotech and pharma companies navigating chemical regulations, potentially affecting R&D investment, product approvals, and market positioning for bio-based alternatives.
Full story: https://getbiobrief.com/story/epa-maha-bio-regulatory-uncertainty

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.